DBV Technologies S.A.
NASDAQ:DBVTBiotechnology
-$0.16 today
- Market cap
- $238.98M
- Beta
- -0.22
- P/E (TTM)
- -8.3
- EPS (TTM)
- -$0.39
Volume 0.17M
Average 0.24M
DBVT Operating Expenses
Total costs of running the business that are not directly tied to producing goods or services sold.
DBV Technologies S.A.NASDAQ: DBVT
Operating Expenses · Q1 FY2026 · quarter ended Mar 2026
Operating expenses growth accelerates
Q1 FY2026 operating expenses of $47.9M rose 80.0% year over year, ahead of the +44.9% change in trailing-twelve-month operating expenses. Sequentially, it rose 6.3% from the prior quarter. Over 3 fiscal years it compounded at +13.2% a year.
Context
- Operating expenses increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +80.0% holds above the trailing-twelve-month pace of +44.9%.
Sources:Income StatementText generated from reported figures; not investment advice.
Operating Expenses history
USD · from the income statement
- Latest · FY2025
- 147.06M USD
- Year-over-year change
- +29.3%
- 4-year CAGR
- +11.9%
| Period | Period end | Operating Expenses | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 147.06M | +29.3% |
| FY2024 | 2024-12-31 | 113.71M | +23.4% |
| FY2023 | 2023-12-31 | 92.16M | -9.2% |
| FY2022 | 2022-12-31 | 101.48M | +8.0% |
| FY2021 | 2021-12-31 | 93.93M | — |
Operating Expenses vs competitors
How DBVT compares with its peers on the latest reported figures
- DBVT's LTM Mar 2026 operating expenses of $164.05M is the 3rd highest of the 11 companies compared; the peer median is $99.5M.
- Its year-over-year change of +44.9% is the 3rd highest of 10, against a peer median of -11.1%.
- Over three fiscal years its annual growth of +13.2% compares with a peer median of +18.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $203.15M | +11.1% | +13.5% | — | |
| LTM Mar 2026 | $172.43M | +63.7% | +67.8% | — | |
| LTM Mar 2026 | $164.05M | +44.9% | +13.2% | — | |
| LTM Mar 2026 | $150.13M | -11.1% | -27.1% | 69.9% | |
ENGNenGene Holdings Inc. | LTM Apr 2026 | $132.21M | +50.3% | +85.1% | — |
| LTM Mar 2026 | $101.75M | +11.1% | -1.4% | 149.4% | |
LXEOLexeo Therapeutics, Inc. Common Stock | LTM Mar 2026 | $97.24M | -16.4% | +21.3% | — |
| LTM Mar 2026 | $85.57M | -14.7% | +14.9% | 2227.3% | |
| LTM Mar 2026 | $81.97M | -16.5% | +2.5% | 227697.2% | |
LBRXLB Pharmaceuticals Inc Common Stock | LTM Mar 2026 | $46.78M | — | +121.2% | — |
| LTM Mar 2026 | -$55.19M | -179.1% | +31.6% | — | |
| Peer median (excluding DBVT) | $99.5M | -11.1% | +18.1% | 1188.3% | |
Competitors are the stored peer set for DBVT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 5.71M | 4.8M | 15.73M | 0 | 0 |
| Cost of Revenue | 9.27M | 20.3M | 0 | 6.81M | 17.67M |
| Gross Profit | (3.57M) | (15.5M) | 15.73M | (6.81M) | (17.67M) |
| Gross Margin | -62.5% | -322.9% | 100.0% | — | — |
| Research & Development | 70.34M | 75.5M | 60.22M | 89.9M | 116.68M |
| Selling, General & Admin | 23.83M | 17.56M | 31.94M | 23.81M | 28.28M |
| Operating Expenses | 93.93M | 101.48M | 92.16M | 113.71M | 147.06M |
| Depreciation & Amortization | 8.38M | 20.3M | 13.16M | 6.81M | 7.73M |
| EBITDA | (91.16M) | (76.68M) | (63.27M) | (110.99M) | (139.32M) |
| EBITDA Margin | -1597.0% | -1597.5% | -402.3% | — | — |
| Operating Income | (98.61M) | (96.63M) | (76.43M) | (120.53M) | (147.06M) |
| Operating Margin | -1727.6% | -2013.1% | -486.0% | — | — |
| Interest Income | 521K | 406.29K | 3.71M | 2.73M | 601.86K |
| Interest Expense | 690K | 427K | 0 | 0 | 0 |
| Other Income / Expenses | 424K | 427K | 3.71M | 2.73M | 600K |
| Income Before Tax | (98.19M) | (96.2M) | (72.72M) | (117.8M) | (146.46M) |
| Pre-Tax Margin | -1720.2% | -2004.3% | -462.4% | — | — |
| Income Tax Expense | (381K) | 70K | 7K | (4.08M) | 491K |
| Net Income | (97.81M) | (96.3M) | (72.73M) | (113.72M) | (146.95M) |
| Net Margin | -1713.5% | -2006.3% | -462.4% | — | — |
| EPS (Basic) | (1.80) | (1.25) | (0.75) | (1.20) | (1.70) |
| EPS (Diluted) | (1.80) | (1.25) | (0.75) | (1.20) | (1.70) |
| Weighted Avg Shares | 55.1M | 77.38M | 95.12M | 96.17M | 86.4M |
| Weighted Avg Shares (Diluted) | 55.1M | 77.38M | 95.12M | 96.17M | 86.4M |
DBV Technologies S.A.
NASDAQ:DBVT
Intrinsic Alpha fair value
Locked
Current Price
$9.99
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.